Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, July 07, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Infant Medicine Syringes Market Size, Trends and Insights By Type (Oral Syringes,...
-
Austin, TX, USA, July 07, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Infant Heart Monitor Market Size, Trends and Insights By Product Type (Video...
-
Austin, TX, USA, July 02, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neonatal Infant Care Market Size, Trends and Insights By Product Type...
-
Austin, TX, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Neonatal Infant Care Market Size, Trends and Insights By Product Type...
-
LOS ANGELES, June 25, 2026 (GLOBE NEWSWIRE) -- The 2026 Baby Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly...
-
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
-
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.
-
Austin, TX, USA, May 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Cholera Vaccine Market Size, Trends and Insights By Type (Whole Cell v. Cholerae...